Lexaria Bioscience (LEXX) EBT Growth (3y) (2020 - 2026)
Lexaria Bioscience (LEXX) EBT Growth (3y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.22% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 12.16% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 103.69% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 24.03% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 41.79% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 38.36% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -27.69% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 64.03% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -38.56% |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | 6.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 6.02% |
| Feb 28, 2026 | -2.33% |
| Nov 30, 2025 | 2.88% |
| Aug 31, 2025 | -53.10% |
| May 31, 2025 | -15.34% |
| Feb 28, 2025 | -21.27% |
| Nov 30, 2024 | -9.01% |
| Aug 31, 2024 | -17.68% |
| May 31, 2024 | -1.22% |
| Feb 29, 2024 | 2.40% |
| Nov 30, 2023 | -404.91% |
| Aug 31, 2023 | -3.66% |
| May 31, 2023 | -17.47% |
| Feb 28, 2023 | -5.39% |
| Nov 30, 2022 | 2.99% |
| Aug 31, 2022 | 26.79% |
| May 31, 2022 | -1.21% |
| Feb 28, 2022 | -7.46% |
| Nov 30, 2021 | 13.07% |
| Aug 31, 2021 | 44.12% |